Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Assets: 2019-2024

Historic Assets for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $202.6 million.

  • Silence Therapeutics' Assets rose 19.53% to $146.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.8 million, marking a year-over-year increase of 19.53%. This contributed to the annual value of $202.6 million for FY2024, which is 69.64% up from last year.
  • As of FY2024, Silence Therapeutics' Assets stood at $202.6 million, which was up 69.64% from $119.4 million recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' Assets peaked at $202.6 million during FY2024, and registered a low of $11.6 million during FY2020.
  • Its 3-year average for Assets is $116.5 million, with a median of $119.4 million in 2023.
  • Its Assets has fluctuated over the past 5 years, first plummeted by 56.43% in 2020, then surged by 337.27% in 2023.
  • Over the past 5 years, Silence Therapeutics' Assets (Yearly) stood at $11.6 million in 2020, then increased by 0.84% to $11.7 million in 2021, then spiked by 132.86% to $27.3 million in 2022, then soared by 337.27% to $119.4 million in 2023, then spiked by 69.64% to $202.6 million in 2024.